126 results about "Precursor Muscle Cells" patented technology

The invention provides a marker of spinal cord functional neural precursor cells, a detection method and a sorting method, and belongs to the technical field of biological medicine. The invention provides application of a marker detection reagent in preparation of a kit for detecting spinal cord functional neural precursor cells. The invention further provides a sorting-based method for separating the SFNPCs cells, and the cells are sorted through the Marker of the specific SFNPCs, so that the cell purity of the SFNPCs is remarkably improved, the difference between batches is reduced, and a high-purity and homogeneous SFNPCs cell population is obtained. The survival rate of the SFNPCs cells separated and subcultured to the P9 generation by the method disclosed by the invention is more than 85%, and the SFNPCs cells have a good treatment effect on a spinal cord injury model.

The invention discloses a chicken myoblast and chicken fat precursor cell co-culture synchronous differentiation method and application thereof, and belongs to the technical field of animal cell co-culture and differentiation. The method comprises the following steps: respectively carrying out in-vitro multiplication culture on chicken myoblasts and chicken fat precursor cells, carrying out mixed co-culture, inducing for at most two days by adopting horse serum with the volume percent of 0.5-2%, carrying out pre-differentiation, and continuously carrying out induced differentiation culture for at most one day by using an induced adipogenesis culture medium. According to the synchronous differentiation method for co-culture of the chicken myoblasts and the chicken fat precursor cells, a cell co-culture system is constructed, time sequence induced differentiation is achieved, and a final product with fat droplets distributed in the gaps of muscle bundles (the average distance is 20-50 microns) and capable of recarving natural chicken intermuscular fat textures is obtained. According to the method, the differentiation period is shortened to be within 3 days from 21 days (the efficiency is improved by 600%); the induction cost is reduced by 42.7%; the final product breaks through the sensory acceptance barrier through bionic structure recarving.

Disclosed are in vitro methods for the differentiation of precursor cells into a neural crest cell (NCC) primed to a neurogenic lineage. The methods may include, for example, the steps of activating a Hedgehog signaling pathway (“HH signaling pathway”) in a precursor cell, wherein the precursor cell may be contacted with a neural crest cell induction medium for differentiation of the precursor cell into a neural crest cell. Compositions for carrying out the disclosed methods are also disclosed.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

Provided are a reagent combination or a kit for constructing an embryoid and the use thereof. The reagent combination or the kit can be used for inducing a stem cell to produce a blastocyst-like lineage precursor cell, a blastocyst-like cell and / or an embryoid, which are based on small-molecule induction and independent of transgenes, and have a single cell source. The produced blastocyst-like lineage precursor cell and blastocyst-like cell have a full blastocyst lineage, and are seed cells having balanced developmental competence and totipotency, which solves the problem of unbalanced cell maturation in the prior art. The produced embryoid is highly similar to natural embryos in terms of morphological characteristics and transcriptomic characteristics, has the capability of highly reproducing post-implantation embryonic development and / or gastrulation, which is beneficial for research on embryonic development in vitro. The method for inducing the stem cell to produce the blastocyst-like lineage precursor cell, the blastocyst-like cell and / or the embryoid by using the reagent combination or the kit is simple, and has high applicability and high embryoid construction efficiency.

The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.

This invention relates to the regulation of pancreatic islet cell differentiation by regulatory factors related to N6-adenosine methylation modification of mRNA. Specifically, it relates to the use of (a) the ALKBH5 gene, or its protein, or its promoter; and / or (b) the YTHDF2 gene, or its protein, or its inhibitor, for the preparation of compositions or formulations for (1) promoting the differentiation of endodermal cells into pancreatic islet precursor cells and / or islet organoids; and / or (2) preventing and / or treating diabetes. The ALKBH5 of this invention regulates the N6-adenosine methylation modification of mRNA by... 6 Modification A controls the in vitro differentiation process of human pancreatic cells. Furthermore, the method of this invention holds promise as an effective method for in vitro culture of pancreatic islet cells, and could subsequently be applied to the treatment of diabetes.

To provide a method for evaluating the therapeutic and / or prophylactic action of a skin disease caused by the obstruction and / or inflammation of a pilosebaceous gland system.SOLUTION: A method for evaluating a therapeutic and / or prophylactic action of a substance or agent on a skin disease, the method comprising: bringing the substance or agent into contact with sebocytes or progenitor cells thereof; and evaluating the sebocytes or progenitor cells thereof, wherein the skin disease is a skin disease caused by obstruction and / or inflammation of the pilosebaceous unit.SELECTED DRAWING: None

The invention relates to a method of differentiating pancreatic bi-potent progenitor cells into beta cells comprising cultivating pancreatic endocrine precursor cells in a medium that promotes the cAMP signalling pathway that lies downstream of apical-basal polarity in endocrine precursors, which can be used to increase the differentiation of progenitor cells into beta cells. Furthermore, the present invention relates to a method of enriching and / or isolating one or more cells expressing a marker of apical-basal polarity, thereby isolating beta cells, and to a method of producing a population of beta cells from a population of human embryonic stem cells. Furthermore, the present invention relates to a population of beta cells obtainable by the method, a pharmaceutical composition comprising the beta cells, a cell culture of progenitor cells in a medium comprising a cAMP agonist, a complex comprising a beta cell bound by the binding agents specific for CD133 and CD49a, and a use of specific binding partners for isolating beta cells.

A method of direct transdifferentiation of somatic cells into other somatic cells may be convenient and still have good reproducibility, excellent production efficiency, and short performed time. Methods for direct transdifferentiation of somatic cells into other somatic cells may include: (a) introducing a GLIS family gene, a mutated GLIS family gene or a gene product thereof into somatic cells; and (b) culturing the gene-introduced somatic cells in a culture medium containing a component that induces differentiation of the somatic cells or precursor cells of the somatic cells into other somatic cells.

The present application relates to a kind of RANKL / NLRP3 dual-target inhibitor and its preparation method and application, belong to the field of pharmaceutical chemistry and biomedical technology.The indole compound, its optical isomer, pharmaceutically acceptable salt and hydrate provided by the present application have RANKL and NLRP3 dual-target inhibition activity, can be inhibited by inhibiting RANKL-RANK interaction, and inhibit inflammasome NLRP3 activity, regulate RANKL activity in osteoclast precursor cell, inhibit the formation of osteoclast, thereby reduce bone resorption, and improve the inflammatory response caused by rheumatoid arthritis, is expected to play the prevention and treatment of bone metabolic disease.

The present invention relates to compositions comprising photoreceptor precursor cells (PRPs), as well as methods of generating the composition of PRPs and methods of using the composition of PRPs for regenerative cell therapy.

The present application relates to the technical field of medicine, and more particularly to the application of beta-hydroxybutyric acid in the preparation of a drug for preventing and / or treating osteoporosis, including postmenopausal osteoporosis due to estrogen deficiency and diabetic osteoporosis, wherein the concentration of the beta-hydroxybutyric acid is 150 mM, the application of beta-hydroxybutyric acid in the preparation of a drug for inhibiting the differentiation of osteoclasts or inhibiting the formation of osteoclasts, wherein the beta-hydroxybutyric acid inhibits the differentiation of osteoclast precursor cells into osteoclasts, and the concentration of the beta-hydroxybutyric acid is 10 mM; the present application proves that beta-hydroxybutyric acid improves the bone microstructure of OVX mice and db / db mice, inhibits the differentiation of osteoclasts, and reduces bone resorption, thereby providing a new target for the prevention and treatment of osteoporosis.

The application discloses a method for differentiating stem cells into caudal serotonergic neurons, a complete culture medium and application. Specifically, a new culture medium is formed by adding small molecule compounds, so that human pluripotent stem cells are gradually induced to obtain hindbrain neural stem cells, ventral hindbrain caudal neural stem cells, serotonergic precursor cells and caudal serotonergic neurons of the hindbrain. The culture method is simple, and can efficiently obtain mature serotonergic neurons of specific regions, thereby providing an effective cell model for research on diseases related to the serotonergic system.

Compositions and methods for modifying a muscle or muscle precursor cell genome are disclosed. Also provided are methods of treatment using the compositions.

The invention discloses an application of a branched ketonic acid dehydrogenase kinase (BCKDK) inhibitor in preparation of a medicine for preventing and treating osteoporosis. The invention finds that BCKDK can inhibit osteoblast differentiation and reduce the expression of endogenous BCKDK in osteogenic precursor cells so as to promote osteoblast differentiation; a small molecule compound inhibitor BT2 (3, 6-dichloro-2-benzothiophene carboxylic acid) of BCKDK promotes osteoblast differentiation of ovariectomized mice, inhibits osteoclast differentiation, reduces ovariectomized mouse bone loss and increases bone mass. According to the invention, the BCKDK inhibitor is proposed for the first time to be capable of promoting osteoblast differentiation, inhibiting osteoclast differentiation and increasing body bone mass by reducing BCKDK expression or inhibiting BCKDK protein biological functions, and has the effect of preventing and treating osteoporosis.

The present application relates to a preparation method and application of photoreceptor precursor cells of human embryonic stem cell-derived retinal organoids, and belongs to the field of biotechnology and stem cell engineering. The present application constructs a lentiviral vector carrying an exogenous target gene and infects human embryonic stem cells to obtain a stable expression of engineered stem cell clone group by screening; the clone group is subjected to three-dimensional differentiation, and sequentially undergoes the formation of a blastoid, neural epithelial induction and retinal layering stage to obtain a retinal organoid; finally, the co-expression of photoreceptor precursor cell markers and exogenous genes in the organoid is identified. The present application realizes stable integration of genes at the source of stem cells, avoids the problem of low infection efficiency in the later stage, and provides a complete standardized scheme from gene modification, directional differentiation to function verification. The engineered photoreceptor precursor cells obtained by the method have important application value in the construction of retinal disease models, drug screening and cell therapy development.

The application discloses an induction method for directional differentiation of neural stem cells into dopaminergic neurons, comprising the following steps: S1, activation and adhesion of NSCs; S2, directional induction of midbrain precursor cells; S3, directional induction of dopaminergic neurons; and S4, synaptic function maturation induction. The induction method for directional differentiation of neural stem cells into dopaminergic neurons can significantly improve the directional efficiency and lineage specificity of the midbrain precursor cells: by adding salvianolic acid B and icariin, and in cooperation with SHH, FGF8 and other induction factors, the midbrain lineage-specific signal pathway can be efficiently activated, the positive rate of the midbrain precursor cell marker LMX1A is increased to more than 76%, which is far better than 49% of the existing system, and abnormal differentiation of non-midbrain lineages is effectively inhibited.

Provided is a method for production by direct transdifferentiation of somatic cells into another somatic cells which is convenient, has good reproducibility, is excellent in production efficiency, and is performed in a short period of time. The method for production by direct transdifferentiation of somatic cells into another somatic cells comprises: (a) a step of introducing a GLIS family gene, a mutated GLIS family gene or a gene product thereof into somatic cells; and (b) a step of culturing the gene-introduced somatic cells in a culture medium containing a component that induces differentiation of the somatic cells or precursor cells of the somatic cells into another somatic cells.

The present application relates to a kind of pig hair follicle matrix precursor cell identification method and its application.The present application uses OGN and UCHL1 as the marker gene of pig hair follicle matrix precursor cell, the gene number of the OGN in NCBI database is 106509723, the gene number of the UCHL1 in NCBI database is 396637, the identification method is: pig embryo epidermal cell is immunofluorescence dyeing, OGN and UCHL1 can be simultaneously detected cell is pig hair follicle matrix precursor cell, the pig embryo refers to the embryo of pig embryo period 37 days and before.This application provides the identification method of pig hair follicle matrix precursor cell, and is applied in hair follicle development research.The present application discloses that OGN and UCHL1 are more suitable as the marker gene of pig hair follicle matrix precursor cell than BMP7 and TGF beta 2.

The present disclosure provides methods of manufacturing cell-laden scaffolds comprising lipid-producing cells comprising confining lipid-producing precursor cells in a three-dimensional (3D) environment and culturing the lipid- producing precursor cells confined in the 3D environment in a food-grade differentiation medium to obtain the cell-laden scaffold comprising lipid-producing cells. In one embodiment, the 3D environment is formed by a mixture comprising lipid-producing precursor cells and a food-grade polymericsolution, wherein the food-grade polymeric solution comprises one or more selected from the group consisting of alginate, gelatin, pectin, agarose, carrageenan, gellan gum, konjac glucomannan, cellulose, etc. and combinations thereof, the lipid-producing precursor cells are selected from the group consisting of adipose-derived stem cells, preadipocytes mesenchymal stem cells, embryonic stem cells, induced- pluripotent stem cells and combinations thereof, the lipid-producing cells are selected from adipocytes, hepatocytes, sebocytes, mammary epithelia cells, keratinocytes and combinations thereof, and the food-grade differentiation medium comprises a fatty acid.

The invention discloses a nerve cell differentiated from an immunoprivilege induced pluripotent stem cell and an application thereof. After main histocompatibility complex HLA-I and II type genes are inactivated in induced pluripotent stem cells, fusion protein XSG006 constructed by functional structural domains of CD47 and CD24 is over-expressed, the obtained induced pluripotent stem cells are differentiated to obtain separated low-immunogenicity dopaminergic neural precursor cells, and the low-immunogenicity dopaminergic neural precursor cells can be used for preparing the low-immunogenicity dopaminergic neural precursor cells on the basis of attack of escape T cells. And further, the NK cells and macrophages are escaped for killing. And attacks of an immune system can be effectively escaped in vivo. In a mouse Parkinson's disease model and a non-human primate (NHP) Parkinson's disease model, the strain can continuously survive in a host for a long time and generate activity, and the Parkinson's disease is fundamentally reversed. And an experimental basis and a theoretical basis are provided for establishing a PD treatment strategy and designing a novel stem cell treatment medicine.

Provided are an induced NK cell, and a preparation method therefor and the use thereof. The method comprises mixing a CD34+ cell with a stromal cell, co-culturing the mixture to obtain an NK precursor cell, and subjecting the NK precursor cell to induction and amplification culture to obtain a mature NK cell, wherein the stromal cell comprises any one or a combination of at least two of an AFT024 cell, an MS5 cell, an OP9 cell, an HS-5 cell, an MSC cell, an MUTZ-3 cell, a stromal cell derived from tissues such as bone marrow or the liver, or a primary cell. Provided is the development of a brand-new method for inducing an NK cell on the basis of a CD34+ cell, which enables the induction of the NK cell with a high efficiency. The efficiency of outputting NK cells from a single CD34+ cell is improved, and the property of the induced NK cell is very close to that of a natural mature NK cell. They have uniform anti-tumor effects, can effectively kill tumor cells, and have broad application prospects.

The application relates to an anti-inflammatory and cartilage regeneration promoting material, a preparation method and application thereof, and belongs to the technical field of biomedical materials. The anti-inflammatory and cartilage regeneration promoting material comprises a PLGA (50:50) polymer material, and a huperzine A derivative dimer loaded on the PLGA (50:50) polymer material through 3D printing. The application also provides the use of the anti-inflammatory and cartilage regeneration promoting material in the preparation of anti-inflammatory, cartilage protection or cartilage regeneration promoting drugs. The PLGA / A10E scaffold has good biocompatibility, the PLGA / A10E scaffold degradation release liquid can effectively promote the differentiation of cartilage precursor cells into cartilage, and increase the formation of cartilage collagen matrix and cartilage proteoglycan. The in-vitro degradation liquid of the PLGA / A10E scaffold can promote the expression of SOX9 under non-inflammatory conditions; under LPS-mediated inflammatory conditions, the expression of MMP-13 can be inhibited, thereby promoting the synthesis of cartilage matrix and inhibiting the degradation of cartilage matrix.

The application discloses a serum-free adipogenic differentiation method of pig fat precursor cells, relates to the technical field of mammal cell differentiation, and uses an induction differentiation culture medium and a maintenance differentiation culture medium in succession in the adipogenic differentiation process. The induction differentiation culture medium is composed of a basic culture medium and a cell culture auxiliary factor. The cell culture auxiliary factor is composed of 66nmol / L insulin, 33μmol / L biotin, 17μmol / L pantothenic acid, 0.1μmol / L dexamethasone, 0.25mmol / L IBMX, 1μmol / L rosiglitazone, 150μmol / L sodium oleate and 10μg / mL transferrin. The maintenance differentiation culture medium removes the IBMX and rosiglitazone on the basis of the induction differentiation culture medium. The serum-free adipogenic differentiation method of pig fat precursor cells has good differentiation effect and high repeatability.

Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclosure describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons. The present disclosure also relates to compositions of cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons, and their precursors, that are highly enriched and can be used in variety of application. These cells can be used therapeutically to treat neurodegenerative and neuropsychiatric disorders, and can be used for disease modeling and drug screening.

The invention relates to the technical field of medicines, in particular to application of allogenic liver precursor cells in preparation of a medicine for treating liver cirrhosis, and the liver cirrhosis is decompensated liver cirrhosis. The allogenic liver precursor cells degrade extracellular matrix, fibroblast growth factor (FGF) and hepatocyte growth factor (HGF) through paracrine MMPs to promote hepatocyte regeneration and repair and the like, so that the liver cirrhosis is relieved and improved.

The present invention relates to a pharmaceutical composition for preventing or treating renal diseases, comprising, as an active ingredient, exosomes isolated from precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells, the precursor cells having been treated or not having been treated with a pretreatment material. Exosomes of the present invention exhibit an effect of preventing or treating renal diseases that is more improved than that of exosomes isolated from conventional mesenchymal stem cells, thereby being effectively usable for relevant research and development and productization.